China Pharma Holdings (CPHI) Cash from Investing Activities Growth (3y) (2013 - 2025)
China Pharma Holdings (CPHI) Cash from Investing Activities Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | China Pharma Holdings | 41.34 Mn | 41.03 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.29% |
| Sep 30, 2025 | 45.63% |
| Jun 30, 2025 | 42.94% |
| Mar 31, 2025 | -247.41% |
| Dec 31, 2024 | -238.16% |
| Sep 30, 2024 | 26.46% |
| Dec 31, 2023 | -26.40% |
| Sep 30, 2023 | 36.17% |
| Jun 30, 2023 | 26.18% |
| Mar 31, 2023 | 29.28% |
| Dec 31, 2022 | 36.49% |
| Sep 30, 2022 | -174.57% |
| Jun 30, 2022 | -712.52% |
| Mar 31, 2022 | 73.40% |
| Dec 31, 2021 | 26.56% |
| Sep 30, 2021 | -398.89% |
| Dec 31, 2020 | 75.04% |
| Sep 30, 2020 | -155.71% |
| Jun 30, 2020 | -169.46% |
| Mar 31, 2020 | -135.50% |